Avoiding arrythmias by personalizing the dialysate concentration: a case for precision medicine in patients on dialysis.
| Autor: | Ikizler TA; Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Electronic address: alp.ikizler@vanderbilt.edu., Drueke TB; Inserm Unit 1018, Team 5, CESP, Paul Brousse Hospital, Paris, France., Floege J; Division of Nephrology and Rheumatology, Rheinisch Westfälische Technische Hochschule (RWTH) University of Aachen, Aachen, Germany., Wong G; The University of Sydney, Sydney, New South Wales, Australia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Kidney international [Kidney Int] 2024 Oct 26. Date of Electronic Publication: 2024 Oct 26. |
| DOI: | 10.1016/j.kint.2024.10.009 |
| Abstrakt: | Cardiac arrythmias are common in patients undergoing maintenance hemodialysis. In this issue, Charytan et al. showed that in patients with hyperkalemia (serum potassium concentration 5.1-6.5 mEq/l) on hemodialysis, a dialysate concentration of 3 mEq/l combined with sodium zirconium cyclosilicate on dialysis-free days is associated with a low frequency of atrial fibrillation compared with a dialysate concentration of 2 mEq/l over 8 weeks. Despite the obvious limitations such as small sample size, short treatment period, and absence of information on longer-term impact regarding patient important outcomes such as sudden death, this well-conceived pilot study provided impetus for larger prospective trials to test whether this personalized approach reduces major cardiovascular events and mortality. (Copyright © 2024 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|